[Form 4] IDEXX LABORATORIES INC /DE Insider Trading Activity

IDEXX Laboratories Executive Vice President George Fennell reported a series of routine equity compensation transactions.

Rhea-AI Filing Summary

IDEXX Laboratories Executive Vice President George Fennell reported a series of routine equity compensation transactions. On February 12, 2026, he received grants of 3,384 non-qualified stock options, 162 incentive stock options, and 810 restricted stock units (RSUs), each representing the right to receive one share of common stock as they vest over future years.

On February 14, 2026, previously granted RSUs vested and were converted into common shares through derivative exercises, and 199 common shares were withheld at $629.35 per share to satisfy tax obligations. After these transactions, Fennell directly held 10,078 shares of IDEXX common stock.

Insider Trade Summary

454 shares exercised/converted

Exercise 12 txns

Insider FENNELL GEORGE

Role Executive Vice President

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	55	$0.00	$0.00
Exercise	Restricted Stock Unit	56	$0.00	$0.00
Exercise	Restricted Stock Unit	139	$0.00	$0.00
Exercise	Restricted Stock Unit	204	$0.00	$0.00
Exercise	Common Stock	55	$0.00	$0.00
Exercise	Common Stock	56	$0.00	$0.00
Exercise	Common Stock	139	$0.00	$0.00
Exercise	Common Stock	204	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	199	$629.35	$125K
Grant/Award	Non-Qualified Stock Option (right-to-buy)	3,384	$0.00	$0.00
Grant/Award	Incentive Stock Option (right-to-buy)	162	$0.00	$0.00
Grant/Award	Restricted Stock Unit	810	$0.00	$0.00

Holdings After Transaction: Non-Qualified Stock Option (right-to-buy) — 3,384 contracts (Direct); Incentive Stock Option (right-to-buy) — 162 contracts (Direct); Restricted Stock Unit — 1,756 contracts (Direct); Common Stock — 10,078 shares (Direct)

Footnotes (8)

1. F1. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
2. F2. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
3. F3. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
4. F4. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.
5. F5. Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023.
6. F6. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024.
7. F7. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
8. F8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 07:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FENNELL GEORGE

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/14/2026		M		55	A	$0	9,878	D
Common Stock	02/14/2026		M		56	A	$0	9,934	D
Common Stock	02/14/2026		M		139	A	$0	10,073	D
Common Stock	02/14/2026		M		204	A	$0	10,277	D
Common Stock	02/14/2026		F		199	D	$629.35(1)	10,078	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)	$617.2	02/12/2026		A		3,384		(2)	02/11/2036	Common Stock	3,384	$0	3,384	D
Incentive Stock Option (right-to-buy)	$617.2	02/12/2026		A		162		(3)	02/11/2036	Common Stock	162	$0	162	D
Restricted Stock Unit	(4)	02/12/2026		A		810		(4)	(4)	Common Stock	810	$0	810	D
Restricted Stock Unit	(5)	02/14/2026		M			55	(5)	(5)	Common Stock	55	$0	0	D
Restricted Stock Unit	(6)	02/14/2026		M			56	(6)	(6)	Common Stock	56	$0	56	D
Restricted Stock Unit	(7)	02/14/2026		M			139	(7)	(7)	Common Stock	139	$0	278	D
Restricted Stock Unit	(8)	02/14/2026		M			204	(8)	(8)	Common Stock	204	$0	612	D

Explanation of Responses:

1. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.

2. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.

3. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.

4. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.

5. Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023.

6. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024.

7. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.

8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for George Fennell	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.